Olaparib monotherapy is already approved by the FDA for the treatment of the BRCA1/2 mutant, homologous recombination repair-deficient pancreatic cancer, and Parsels et al. [89] could show that olaparib-mediated DNA damage is amplified by ATR inhibition and correlates with radiosensitization. Here, ATR is linked to familial pancreatic carcinoma.